Biocatalysis for pharmaceutical intermediates: the future is now

Trends in Biotechnology

Volumn 25, Issue 2, 2007, Pages 66-73

  Pollard, David J ^a   Woodley, John M ^b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCATALYSTS; BIOTECHNOLOGY; CHROMATOGRAPHY; SEPARATION;

BIOCATALYSIS; CHEMOCATALYSIS; CHROMATOGRAPHIC SEPARATIONS; OPTICAL PURITY;

DRUG PRODUCTS;

APREPITANT; ATORVASTATIN; DORZOLAMIDE; INDINAVIR; OSELTAMIVIR;

BIOCATALYST; BIOENGINEERING; BIOPROCESS; CATALYSIS; DEVELOPMENT; DRUG INDUSTRY; DRUG SYNTHESIS; ENANTIOMER; PRIORITY JOURNAL; PROCESS DEVELOPMENT; RECOMBINANT DNA TECHNOLOGY; REVIEW; TECHNOLOGY;

BIOTRANSFORMATION; CATALYSIS; CHEMISTRY, PHARMACEUTICAL; DRUG INDUSTRY; ENZYMES, IMMOBILIZED; MODELS, CHEMICAL; PHARMACEUTICAL PREPARATIONS;

EID: 33846197938     PISSN: 01677799     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tibtech.2006.12.005     Document Type: Review

References (91)

1. Bornscheuer U.T., and Kazlauskas R.J. Hydrolases in Organic Synthesis - Regio- and Stereoselective Biotransformations (1999), Wiley-VCH
2. In: Liese A., Seelbach K., and Wandrey C. (Eds). Industrial Biotransformations (2000), Wiley-VCH
3. Patel R.N. Stereoselective Biocatatalysis (2000), Dekker
4. Drauz K., and Waldmann H. Enzyme Catalysis in Organic Synthesis. 2nd edn Vols 1-3 (2002), Wiley-VCH
5. Bommarius A.S., and Riebel B.R. Biocatalysis Vol. 1 (2004), Wiley-VCH
6. Faber K. Biotransformations in Organic Chemistry. 4th edn (2004), Springer
7. Cao L. Carrier-bound Immobilized Enzymes (2005), Wiley-VCH
8. Buchholtz K., et al. Biocatalysts and Enzyme Technology (2005), Wiley-VCH
9. Schmid A., et al. Industrial biocatalysis today and tomorrow. Nature 409 (2001) 258-268
10. Schoemaker H.E., et al. Dispelling the myths - biocatalysis in industrial synthesis. Science 299 (2003) 1694-1697
11. Patel R.N. Microbial/enzymatic synthesis of chiral pharmaceutical intermediates. Curr. Opin. Drug. Discov. Devel. 6 (2003) 902-920
12. Buckland B.C., et al. Biocatalysis for pharmaceuticals - status and prospects for a key technology. Metab. Eng. 2 (2000) 42-48
13. Pesti J.A., and DiCosimo R. Recent progress in enzymatic resolutions and desymmetrization of pharmaceuticals and their intermediates. Curr. Opin. Drug Discov. Devel. 6 (2003) 884-901
14. Yazbeck D.R., et al. Challenges in the development of an efficient enzymatic process in the pharmaceutical industry. Tet. Asymm. 15 (2004) 2757-2763
15. Rozzell J.D. Commercial scale biocatalysis: myths and realities. Bioorg. Med. Chem. 7 (1999) 2253-2261
16. Rouchi M.A. Chiral roundup. Chem. Eng. News. 80 (2002) 43-50
17. Buckland B.C., et al. Microbial conversion of indene to indandiol a key intermediate in the synthesis of Crixivan. Metab. Eng. 1 (1999) 63-74
18. Service R.F. Surviving the blockbuster syndrome. Science 303 (2004) 1796-1799
19. Borman S. Improving efficiency. Chem. Eng. News 84 (2006) 56-78
20. Truppo M.D., et al. Optimization and scale up of a lipase catalyzed enzymatic resolution of an indole ester intermediate for a prostanglandin DP receptor antagonist targeting allergic rhinitis. Org. Proc. Res. Dev. 10 (2006) 592-598
21. Straathof A.J.J., et al. The production of fine chemicals by biotransformation. Curr. Opin. Biotechnol. 13 (2002) 548-556
22. Pollard D., et al. Effective synthesis of (S)-3,5-bistrifluoromethylphenyl ethanol by asymmetric enzymatic reduction. Tet. Asymm. 17 (2006) 554-559
23. Woodley J.M. Choice of biocatalyst form for scalable processes. Biochem. Soc. Trans. 34 (2006) 301-303
24. Cao L. Immobilised enzymes: science or art?. Curr. Opin. Chem. Biol. 9 (2005) 217-226
25. Lye G.J., and Woodley J.M. Application of in situ product-removal techniques to biocatalytic processes. Trends Biotechnol. 17 (1999) 395-402
26. Hilker I., et al. Preparative scale asymmetric Baeyer-Villiger oxidation using a highly productive 'two-in-one' resin-based in situ SFPR concept. Adv. Synth. Catal. 346 (2004) 203-214
27. Vicenzi J.T., et al. Large-scale stereoselective enzymic ketone reduction with in situ product removal via polymeric adsorbent resins. Enzyme Microb. Technol. 20 (1997) 494-499
28. Stark D., and von Stockar U. In situ product removal (ISPR) in whole-cell biotechnology during the last twenty years. Adv. Biochem. Eng./Biotechnol. 80 (2002) 149-176
29. Buque-Taboada E.M., et al. In situ product removal using a crystallization loop in asymmetric reduction of 4-oxoisophorone by Saccharomyces cerevisiae. Biotechnol. Bioeng. 86 (2004) 795-800
30. Hilker I., et al. On the influence of oxygen and cell concentration in an SFPR whole-cell biocatalytic Baeyer-Villiger oxidation process. Biotechnol. Bioeng. 93 (2006) 1138-1144
31. Pfruender H., et al. Efficient whole-cell biotransformation in a biphasic ionic liquid/water system. Angew. Chem. Int. Ed. Engl. 43 (2004) 4529-4531
32. Sheldon R.A., et al. Biocatalysis in ionic liquids. Green Chem. 4 (2002) 147-151
33. Stahl S., et al. Implementation of a rapid microbial screening procedure for biotransformation activities. J. Biosci. Bioeng. 89 (2000) 367-371
34. Yazbeck D.R., et al. Automated enzyme screening methods for the preparation of enantiopure pharmaceutical intermediates. Adv. Synth. Catal. 345 (2003) 524-532
35. Coppola D.R. CMO-grown innovation and technology. Pharma. Technol. 28 (2004) 36-48
36. Doig S.D., et al. The use of microscale processing technologies for quantification of biocatalytic Baeyer-Villiger oxidation kinetics. Biotechnol. Bioeng. 80 (2002) 42-49
37. Lye G.J., et al. Better biocatalytic processes faster: new tools for the implementation of biocatalysis in organic synthesis. Org. Proc. Res. Dev. 6 (2002) 434-440
38. Lye G.J., et al. Accelerated design of bioconversion processes using automated microscale processing techniques. Trends Biotechnol. 21 (2003) 29-37
39. Micheletti M., et al. Fluid mixing in shaken bioreactors: implications for scale-up predictions from microlitre scale microbial and mammalian cell cultures. Chem. Eng. Sci. 61 (2006) 2939-2949
40. Brandt B., et al. Immobilization of enzymes in microtiter plate scale. Biotechnol J. 1 (2006) 582-587
41. Belder D., et al. Enantioselective catalysis and analysis on a chip. Angew. Chem. Int. Ed. Engl. 45 (2006) 2463-2466
42. Cheng H.-Y., and Ervin J. Intact protein RP-HPLC method development using minimal sample. LC-GC North America 16 Suppl. (2006) 32
43. Chen B.H., et al. Modelling of the Baeyer-Villiger monooxygenase catalysed synthesis of optically pure lactones. Food Bioprod. Process. 80 (2002) 51-55
44. Arnold F.H. Directed evolution: creating biocatalysts for the future. Chem. Eng. Sci. 51 (1996) 5091-5102
45. Dalby P.A. Optimising enzyme function by direct evolution. Curr. Opin. Struct. Biol. 13 (2003) 500-505
46. Hibbert E.G., et al. Directed evolution of biocatalytic processes. Biomol. Eng. 22 (2005) 11-19
47. Burton S.G., et al. The search for the ideal biocatalyst. Nat. Biotechnol. 20 (2002) 37-45
48. Bornscheuer U.T. Trends and challenges in enzyme technology. Adv. Biochem. Eng. Biotechnol. 100 (2005) 181-203
49. Kaluzna I.A., et al. Ketoreductase: stereoselective catalysts for the facile synthesis of chiral alcohols. Tet. Asymm. 16 (2005) 3682-3689
50. Zhu D., et al. Evaluation of substituent effects on activity and enantioselectivity in the enzymatic reduction of aryl ketones. Tet. Asymm. 16 (2005) 1541-1546
51. Muller M., et al. Enzyme-catalyzed regio- and enantioselective ketone reductions. Adv. Biochem. Eng. Biotechnol. 92 (2005) 261-287
52. Nakamura K., et al. Recent developments in asymmetric reduction of ketones with biocatalysts. Tet. Asymm. 14 (2003) 2659-2681
53. Shin J.S., and Kim B.-G. Asymmetric synthesis of chiral amines with omega transaminases. Biotechnol. Bioeng. 65 (1999) 206-211
54. Doig S.D., et al. Characterization of a recombinant Escherichia coli TOP10[pQR239] whole-cell biocatalyst for stereoselective Baeyer-Villiger oxidations. Enzyme Microb. Technol. 32 (2003) 347-355
55. Menzel A., et al. From enzymes to 'designer bugs' in reductive amination. Eng. Life Sci. 4 (2004) 573-576
56. Bornscheuer U.T., and Buchholz K. Highlights in biocatalysis - historical landmarks and current trends. Eng. Life Sci. 5 (2005) 309-323
57. Garcia-Urdiales E., et al. Enantioselective enzymatic desymmetrization in organic synthesis. Chem. Rev. 105 (2005) 313-354
58. Hummel W., et al. Towards a large-scale asymmetric reduction process with isolated enzymes: expression of an (S)-alcohol dehydrogenase in E. coli and studies on the synthetic potential of this biocatalyst. Adv. Syn. Cat. 345 (2003) 153-159
59. DeSantis G., et al. Creation of a productive, highly enantioselective nitrilase through gene site saturation mutagenesis (GSSM). J. Am. Chem. Soc. 125 (2003) 11476-11477
60. Brady D., et al. Characterisation of nitrilase and nitrile hydratase biocatalytic systems. Appl. Microbiol. Biotechnol. 64 (2004) 76-85
61. Banerjee A., et al. The nitrile-degrading enzymes: current status and future prospects. Appl. Microbiol. Biotechnol. 60 (2002) 33-44
62. Kaul P., et al. Screening for enantioselective nitrilases: kinetic resolution of racemic mandelonitrile to (R)-(-)-mandelic acid by new bacterial isolates. Tet. Asymm. 15 (2004) 207-211
63. North M. Synthesis and applications of non-racemic cyanohydrins. Tet. Asymm. 14 (2003) 147-176
64. Nanda S., et al. A new (R)-hydroxynitrile lyase from Prunus mume: asymmetric synthesis of cyanohydrins. Tetrahedron 61 (2005) 10908-10916
65. Faber K., and Kroutil W. New enzymes for biotransformations. Curr. Opin. Chem. Biol. 9 (2005) 181-187
66. Iwasaki A., et al. Microbial synthesis of chiral amines by (R)-specific transamination with Arthrobacter sp. KNK168. Appl. Microbiol. Biotechnol. 69 (2006) 499-505
67. Rohdich F., et al. Enoate reductases of Clostridia: cloning, sequencing, and expression. J. Biol. Chem. 276 (2001) 5779-5787
68. Kawabata J., and Ueda M. Expression of Clostridium acetobutylicum enoate reductase in E. coli for production of optically active 2-hydroxymethyl-3-arylpropionic acid. Jpn. Kokai Tokkyo Koho. 41 (2005) 21-25
69. Bommarius A., and Polizzi K.M. Novel biocatalysts: recent developments. Chem. Eng. Sci. 61 (2006) 1004-1016
70. Ricoux R., et al. Hemoabzymes: towards new biocatalysts for selective oxidations. J. Immunol. Methods 269 (2002) 39-57
71. Farinas E.T., et al. Directed evolution of a cytochrome P450 monooxygenase for alkane oxidation. Adv. Synth. Catal. 343 (2001) 601-606
72. Boyd D.R., et al. Biocatalytic asymmetric dihydroxylation of conjugated mono- and poly-alkenes to yield enantiopure cyclic cis-diols. Adv. Synth. Catal. 347 (2005) 1081-1089
73. Yildirim S., et al. Recombinant chlorobenzene dioxygenase from Pseudomonas sp. P51: a biocatalyst for regioselective oxidation of aromatic nitriles. Adv. Synth. Catal. 347 (2005) 1060-1072
74. Mihovilovic M.D., et al. Baeyer-Villiger oxidations of representative heterocyclic ketones by whole-cells of engineered Escherichia coli expressing cyclohexanone monooxygenase. J. Mol. Catal. B: Enzym. 11 (2001) 349-353
75. van Loo B., et al. Diversity and biocatalytic potential of epoxide hydrolases identified by genome analysis. Appl. Environ. Microbiol. 72 (2006) 2905-2917
76. Shi J.-J., et al. Progress in biocatalytic conversion of epoxides. Huagong Jishu Yu Kaifa. 34 (2005) 9
77. Xu W., et al. Enantioconvergent hydrolysis of styrene epoxides by newly discovered epoxide hydrolases in mung bean. Org. Lett. 8 (2006) 1737-1740
78. Choi W.J., and Choi C.Y. Production of chiral epoxides: epoxide hydrolase-catalyzed enantioselective hydrolysis. Biotech. Bioproc. Eng. 10 (2005) 167-179
79. Smit M.S. Fungal epoxide hydrolases: new landmarks in sequence-activity space. Trends Biotechnol. 22 (2004) 123-129
80. Hollmann F., et al. Stereospecific biocatalytic epoxidation: the first example of direct regeneration of a FAD-dependent monooxygenase for catalysis. J. Am. Chem. Soc. 125 (2003) 8209-8217
81. Kai K., et al. Preparation of Curvularia fallax halperoxidase and use of the enzyme for production of alkadiene halohydrin and alkadiene epoxide. Jpn. Kokai Tokkyo Koho. 16 (2005) 44-47
82. Geigert J., and Neidleman S.L. In: Laskin A.I. (Ed). Enzymes and Immobilized Cells in Biotechnology: Enzymic Synthesis of Halohydrins and their Conversion to Epoxides (Biotechnology Series 5) (1985), Butterworth-Heinemann 283-296
83. Roth B.D. The discovery and development of Atorvastatin, a potent novel hypolipidemic agent. Prog. Med. Chem. 40 (2002) 1-22
84. Kizaki N., et al. Synthesis of optically active ethyl 4-chloro-3-hydroxybutanoate by microbial reduction. Appl. Microbiol. Biotechnol. 55 (2001) 590-595
85. Greenberg W.A., et al. Development of an efficient, scaleable aldolase-catalyzed process for enantioselective synthesis of statin intermediates. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 5788-5793
86. Lin J.H., et al. The integration of medicinal chemistry, drug metabolism, and pharmaceutical research and development in drug discovery and development. The story of Crixivan, an HIV protease inhibitor. Pharm. Biotechnol. 11 (1998) 233-255
87. Brands K.M.J., et al. Efficient synthesis of NK1 receptor antagonist Aprepitant using a crystallisation-induced diastereoselective transformation. J. Am. Chem. Soc. 125 (2003) 2129-2135
88. Federspiel M., et al. Industrial synthesis of the key precursor in the synthesis of the anti-influenza drug Oseltamivir Phosphate (Ro 64-0796/002, GS-4104-02): ethyl (3R,4S,5S)-4,5-epoxy-3-(1-ethyl-propoxy)-1-cyclohexene-1-carboxylate. Org. Proc. Res. Dev. 3 (1999) 266-274
89. Guo J., and Frost J.W. Synthesis of aminoshikimic acid. Org. Lett. 6 (2004) 1585-1588
90. Blacklock T.J., et al. An enantioselective synthesis of the topically active carbonic anhydrase inhibitor MK-0507: 5,6-dihydro-(S)-4-(ethylamino)-(S)-6-methyl-4H-thieno[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide hydrochloride. J. Org. Chem. 58 (1993) 1672-1679
91. Holt R.A. Microbial asymmetric reduction in the synthesis of a drug intermediate. Chim. Oggi. 14 (1996) 17-20